Oppenheimer Upgrades Amedisys To Outperform, Sets $40 Target By: Benzinga via Benzinga February 08, 2016 at 14:43 PM EST Oppenheimer on Monday issued a report on Amedisys Inc (NASDAQ: AMED) amid signs that the company may be undervalued. The firm ... Read More >> Related Stocks: Amedisys Inc